2016 Biochemical Society Awards announced! Eleven distinguished scientists and exceptional early career researchers have been honoured in the Biochemical Society’s annual Awards. The Awards recognize scientists for the excellence of their work, the profound impact their research has had and also highlight outstanding work by early career researchers. Find out more on the Biochemical Society website.

Latest Collection

Kidney Health & Disease: A collection highlighting recent research papers and commissioned reviews on various aspects of kidney health and disease, including diabetic nephropathy, inflammatory kidney disease and chronic kidney disease.

New Call For Papers

We invite the submission of original papers to one of the following Calls for Papers by the deadline of 30 November 2015:

  1. Post-translational modifications of proteins: clinical implications
  2. Mitochondria: biology and pathology
  3. Obesity and co-morbidities

Meeting Highlights

FEBS 2015: The Biochemical Basis of Life (July 4-9 2015)
FEBS 2015, the 40th FEBS Congress, will explore "The Biochemical Basis of Life". Topics covered include mechanisms of gene expression; membranes, receptors & bioenergetics; molecular neuroscience; and from chemical biology to molecular medicine.
More information available from the Biochemical Society website here.

Carbohydrate Active Enzymes in Medicine and Biotechnology (19-21st August 2015)
Carbohydrate active enzymes are ubiquitous in all kingdoms of life and vital in an abundance of cellular processes, including structural integrity, cell-cell/cell-pathogen interactions and protein folding. Topics include insights into carbohydrate active enzymes in medicine, and more information can be found here.


Michael M. Page, Claudia Stefanutti, Allan Sniderman and Gerald F. Watts

Familial hypercholesterolaemia (FH) is an autosomal co-dominant disorder that markedly raises plasma low-density lipoprotein-cholesterol concentration, causing premature atherosclerotic coronary artery disease. The metabolic defects in FH extend beyond LDL, and may affect triacylglycerol-rich and high-density lipoproteins, lipoprotein(a) and oxidative stress.
Recent advances in understanding of the biology of proprotein convertase subtilisin/kexin type 9 (PCSK9) have further elucidated the regulation of lipoprotein metabolism and led to new drugs for effectively treating FH. The mechanisms of action of PCSK9 inhibitors on lipoprotein metabolism and atherosclerosis, as well as their impact on cardiovascular outcomes and cost-effectiveness, remain to be established.